In this issue:
Guselkumab safety for up to 5 years in moderate-to-severe psoriasis
Cutaneous manifestations induced by checkpoint inhibitors in melanoma
Psoriasis patients' perspectives towards biologic dose reduction
Brodalumab for hidradenitis suppurativa after biologic treatment failures
Dupilumab-associated cutaneous adverse events in atopic dermatitis
Spesolimab for generalised pustular psoriasis flares
Cost-efficacy of biologics vs narrowband ultraviolet B light
Efficacy and safety of biological agents for pemphigoid
Psoriasis biologic therapy and HIV viral load
Biologic use in hidradenitis suppurativa
Please login below to download this issue (PDF)